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Prevalence and Pattern of Craniofacial 
Pain and Headache in Danish Patients with 
Neuromyelitis Optica Spectrum Disorder 
Gebbie Ann Rodriguez Nielsen,1 Helle Hvilsted Nielsen,2 Zsolt Laszlo Illés2 and Parisa Gazerani1
1. Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Aalborg, Denmark;  
2. Department of Neurology, Odense University Hospital, University of Southern Denmark, Odense, Denmark
There is a dearth of knowledge about the pattern of pain and somatosensory alterations that co-exist with neuromyelitis optica spectrum disorder (NMOSD). Understanding the presence and underlying mechanisms will assist in better pain management in these patients. This study sought to identify prevalence and pattern of headache, craniofacial pain and abnormalities in somatosensory function 
within a group of NMOSD patients in Denmark. Six patients (two males, four females; mean age 41.2 ± 8.6 years) participated in a telephone 
interview. Eight questionnaires were used to assess pain, illness perception, fatigue, anxiety and depression. Pain occurred in several regions, 
including the head, face, neck, back and legs. Two patients experienced frequent headaches and one had headaches following neck pain. Pain 
occurred frequently over a 3-month period, ranging from mild to severe and described as ‘burning’ (66.7%), ‘exhausting’ (83.3%) and ‘sharp’ 
(50%). Correlations were found between pain severity and patients’ ‘ability to walk’ (r=0.889), ‘general activity’ (r=0.901), ‘mood’ (r=0.603), 
‘normal work’ (r=0.664), ‘relations with other people’ (r=0.774) and ‘sleep’ (r=0.586). Somatosensory abnormality was only reported in legs. 
While fatigue had a great impact on patients’ daily life, patients did not report that for anxiety and depression. This study demonstrated that 
headaches and craniofacial pain occur frequently in NMOSD. Patients’ function, mobility, mood and sleep were all affected by pain. These 
findings highlight the value of further investigation on headaches, craniofacial and overall pain in NMOSD. 
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Neuromyelitis optica spectrum disorder
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disease of 
the central nervous system (CNS) causing severe inflammation and demyelination of the optic 
nerve (optic neuritis [ON]), the spinal cord (transverse myelitis [TM]) and the brainstem.1,2 There is a 
dearth of epidemiological data on the prevalence of NMOSD; conclusive data on the occurrence of 
NMOSD are lacking and worldwide there are few epidemiological studies on the disorder.3–5 It has 
been estimated that the prevalence of NMOSD ranges from 1.0–4.4 out of 100,000 in the Western 
world (Europe and North America).3,6 Strikingly, more women are diagnosed with NMOSD than 
men (ratio 9:1).3 The typical age of disease onset peaks at approximately 35–45 years, however, 
it also has been observed in children and elderly.6 The common clinical presentation of NMOSD 
consists of severe episodes of simultaneously bilateral ON, which in turn causes visual field defect 
or loss of vision.7–9 Spinal cord symptoms range from mild sensory disturbances to complete TM, 
causing tetraplegia, paraplegia or paralysis accompanied by sensory impairments and bladder/
bowel dysfunction.7–9 Brainstem symptoms consist of intractable hiccups or nausea and vomiting, 
also known as area postrema syndrome.8,9 Attacks of ON or myelitis are highly debilitating and if 
left untreated, the prospect of remission would be poor, which as a result will lead to irreversible 
neurological damage and disability.6 In addition to the common core symptoms, pain syndromes 
happen to occur more frequently than first appreciated; however, the underlying mechanisms 
causing these pain conditions in NMOSD have not been fully elucidated.1,6 Despite a large variety 
of pain medications, of which each targets different mechanisms of pain, and the different 
combinations of these medications, NMOSD-associated neuropathic pain is yet unmanageable.7 In 
turn, the everyday life of patients is affected to an extent that significantly lowers their quality of life.1 
A study in 2016 has demonstrated that depression in NMOSD patients is linked to neuropathic pain 
and fatigue if these conditions are poorly treated.10 Better knowledge regarding the mechanisms 
of pain in NMOSD patients is urgently needed in order to expand existing knowledge, which in the 
long run could be beneficial for this group of patients.7
More than 85% of NMOSD patients have reported pain as a major symptom and that, despite the 
frequent use of pain medication (e.g. neuropathic medications, antiepileptic medications, opioids 
and non-opioids), they unceasingly experienced high pain intensities.11 Painful tonic muscle spasms 
and neuropathic pain are the most common pain types in NMOSD, causing burning, sharp, electrical, 
shooting pain, cramps, icy or scalding sensations, or numbness.12 These types of pain highly interfere 
with the quality of life of NMOSD patients.1,11,12 While ON typically causes pain around or behind 
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the eyes and TM causes chest and back pain radiating into the lower 
extremities and motor and sensory problems, data regarding the pattern of 
pain in the craniofacial regions and the prevalence of headache in NMOSD 
has not been reported.1,11–13 Moreover, hyper- and hypophenomena of 
pain (e.g. hyperalgesia, allodynia and paradoxical heat sensations) have 
primarily been reported in areas such as the hand, foot and extremities, 
while knowledge of the pattern of somatosensory changes in the 
craniofacial regions of the NMOSD patients still largely remain limited or 
missing.12 This accentuates the necessity of further investigating patterns 
of pain and somatosensory function in NMOSD14 to identify the underlying 
mechanisms of pain in NMOSD and gain better control.
Study aim
This study aimed to identify the prevalence and pattern of pain, and 
abnormalities of somatosensory function in NMOSD patients, by 
examining sensory hyper- and hypophenomena through a panel of 
questionnaires. Pain patterns in the craniofacial region and headaches 
have rarely been investigated in NMOSD, and this study attempts to 
shed light on this neglected feature. In addition to pain, fatigue and 
depression are common comorbidities in NMOSD,15,16 which highly 
affect patients’ quality of life and may worsen their pain experience. 
Consequently, this study sought to explore the existence and pattern 
of these conditions through questionnaires addressing pain, fatigue 
and depression.
Methods
Study design and experimental setup
The study protocol was communicated with the regional ethics committee 
of the central region in Denmark for obtaining ethical approval, but it was 
confirmed that there was no necessity for an approval on conduction of this 
qualitative study. All patients participated in a phone interview voluntarily 
and it was explained to them that they could withdraw at any time and 
refuse to answer questions without any explanations or any consequences. 
Patients
Patients were recruited through the Department of Neurology at Odense 
University Hospital (OUH), Denmark. Patients were eligible to take part 
in this study if they had been diagnosed with NMOSD according to the 
2015 diagnostic NMOSD criteria,8 were both AQP4 positive and negative 
and aged 18 years or above. Patients were contacted by the investigator 
by telephone a few days before the actual interview and were given a 
short introduction regarding the purpose of the study to allow them to 
consider their participation. Each patient had at least 2 days to reflect 
upon participating before the next contact was made. Patients were 
asked whether they still wished to participate and, in case of acceptance 
and agreement, the actual telephone interview was conducted at an 
agreed date and time. To ensure that all information regarding the study, 
descriptions of questionnaires and questions from the questionnaires 
were similar for each patient interview, thus ensuring homogeneity for 
later analysis, the investigator had a manuscript on hand. The interview 
consisted of eight questionnaires and was designed to take up to one 
hour at the longest, as depicted in Figure 1. Patients were excluded from 
the interview if they withdrew or could not cooperate.
Interviews 
Patients were interviewed by telephone due to the distance between 
the investigator and the patients. Furthermore, the telephone interviews 
were the most convenient way of interviewing patients with vision and/
Patients were recruited from the Department of Neurology at Odense University Hospital (OUH). All patients were contacted by phone and those not answering were not 
included. Prior to the actual interview, patients were introduced to the study purpose and were given 2–4 days consideration to participate. Once they accepted and agreed to 
participate, the actual interview was conducted. BIPQ = Brief Illness Perception Questionnaire; FSMC = Fatigue Scale for Motor and Cognitive Functions; HADS = Hospital Scale 
for Anxiety and Depression; MFIS = Modified Fatigue Impact Scale; OUH = Odense University Hospital; SF-BPI = Short-form Brief Pain Inventory; SF-MPQ = Short-form McGill Pain 
Questionnaire; VRS = Verbal Rating Scale.
Figure 1: Study overview representing the setup and steps taken for the telephone interview 
Assessed for eligibility (OUH)
(8 patients)
1st telephone call Excluded (2 patients)
•  Did not answer telephone call (2) 
Screening (5 min)
•  Name, age, height, weight
• Medications, allergies
BIPQ (10 min)
FSMC (10 min)
SF-MPQ (5 min)
VRS (5 min)
MFIS (10 min)
Questions about pain
perception (5 min)
SF-BPI (5 min)
HADS (10 min)
End
2nd telephone call
Interview
Acceptance and agreement 
of participation
Introduction
to the study
2–4 days
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or mobility disabilities. The investigator (GARN) presented herself as a 
researcher and made it clear that she did not have the qualifications or 
experience to make a medical diagnosis nor treat patients, nor did she 
have a specific allegiance to the Department of Neurology at OUH. 
All questionnaires used for the interview addressed the common 
comorbidities of NMOSD such as pain (including sensory function 
and dysfunction), fatigue and depression. A Danish translation of the 
Short-form Brief Pain Inventory (SF-BPI) and the Short-form McGill 
Pain Questionnaire (SF-MPQ) were used to address pain prevalence, 
localisation on the body, intensity and influence on the everyday life of 
the patient. The Brief Illness Perception Questionnaire (BIPQ), Fatigue 
Scale for Motor and Cognitive Functions (FSMC), Modified Fatigue Impact 
Scale (MFIS), Beck Depression Inventory Fast Screen (BDI-FS) and the 
Hospital Scale for Anxiety and Depression (HADS) were used to address 
fatigue, anxiety and depression, and how it affects the quality of life of 
the patient. In addition to the questionnaires, patients were asked to rate 
their pain experiences with a Verbal Rating Scale (VRS). Patients were 
questioned regarding their pain status in a given body part: their current 
pain, pain during the last week, during the last month, and during the last 
three months. Furthermore, a brief questionnaire regarding the patient’s 
pain perception was used. This questionnaire was specifically designed 
to address hypo- or hyperphenoma of pain, based on questions like ‘Does 
light touch (e.g. with clothing, bed-linen, blankets etc.) intensify pain 
in areas of pain?’. The interview followed a structured interview guide, 
ensuring that all questions were relevant for all patients and to retrieve 
relevant information, however, patients were also given the possibility 
to address issues that were important for them to share. Interviews 
were not audio-recorded and transcribed. All answers to questionnaires, 
additional questions, as well as other related information were reported 
in a case record form during the actual interview.
Statistical analysis
Data collection was made in Excel and analyses were conducted using 
the software SPSS Statistics (version 24, IBM, Armonk, NY, US) with a 
statistical significance level at p<0.05. 
The VRS consisted of a four-point scale with the words ‘no pain’, ‘slight 
pain’, ‘moderate pain’ and ‘severe pain’. Patients were questioned 
regarding their pain status (i.e. their current pain, pain during the last 
week, during the last month and during the last three months) in four 
different body areas: (1) face, head and neck; (2) shoulders, arms and 
hands; (3) chest, stomach and upper/lower back; and, lastly (4), legs and 
feet. Data were analysed with a frequency analysis.
The brief questionnaire about pain and its quality was assessed with 
a six-point scale with the words ‘never’, ‘almost never’, ‘sometimes’, 
‘often’, ‘almost always’ and ‘always’. Data were analysed using frequency 
analysis. Localisation of pain was reported and sketched on illustrations 
of the anterior and posterior surfaces of the body (body-charts), and 
were then superimposed with use of appropriate transparencies 
using a computer-drawing program (Adobe Photoshop CC 2017, 
Adobe, San Jose, CA, US). Characterisation of pain was analysed using 
frequency analysis.
The SF-BPI consisted of a series of numerical rating scales (NRS) (0 = no 
pain to 10 = worst imaginable pain) to address pain (current pain status 
as well as worst and mildest pain in the past 24 hours) (pain severity 
indices). Additionally, the pain-related interferences, i.e. how pain had 
affected patients for the past 24 hours, was addressed on a NRS (0 = no 
interference and 10 = complete interference). A mean NRS for each NRS-
series was calculated and assessed. A Pearson’s correlation analysis was 
computed for the pain severity indices and pain-related interferences. 
The SF-MPQ assesses the characteristics of pain with a series of pain 
descriptors. A frequency analysis was used to assess the amount of 
chosen descriptors. 
The BIPQ is a nine-item questionnaire used to measure illness 
perception. Each item was answered with the help of an 11-point scale 
(0–10). Each of the items represented different dimensions (identity, 
timeline, consequence, personal control, treatment control, concern 
understanding and emotional representation), and higher scores indicate 
stronger endorsement of that item. All scores were added up to reflect 
the overall positivity or negativity of an individual’s illness perceptions. 
The minimum score was 0 and the maximum score was 90. 
FSMC and MFIS were used to assess fatigue with five-point scales (1–5 
for FSMC and 0–4 for MFIS). Then, all scores were compiled. The FSMC 
scores were further divided into two subscales: a mental and a fatigue 
subscale. All items were scaled so that higher scores indicated a greater 
impact of fatigue on a patient’s activities
BDI-FS and HADS were used to address depression using four-point 
scales (0–3). For data obtained from BDI-FS, the total score from each 
item was calculated and used to determine severity of depression, 
where high total scores indicate more severe depressive symptoms. 
Cut-off scores used were as follows: 0–9 indicates minimal depression, 
10–18 indicates mild depression, 19–29 indicates moderate depression, 
and 30–63 indicates severe depression. Questions from the HADS 
questionnaire were divided into two subscales: depression and anxiety. 
A minimum score for each of the two subscales is 0, while a maximum 
score is 21. Cut-off scores were: 0–7 is ‘normal’ (indicates no anxiety 
or depression), 8–10 is ‘borderline abnormal’ (indicates some anxiety or 
depression), and 11–21 is ‘abnormal’ (indicates anxiety or depression).
Results
Six NMOSD patients (four females, two males), with an average age of 
41.2 ± 8.6 years (mean ± standard error of the mean [SE]) and a BMI of 
24.2 ± 0.9 kg/m2 (mean ± SE), participated voluntarily in this study. Two 
out of six patients did not take pain medication on the interview day. 
Eight patients were initially contacted; however, two patients were not 
included in the interviews, since they did not respond to the telephone 
calls. No complication occurred during the interview and no complaint 
was raised. Patient demographic information is detailed in Table 1. 
Pain
Pain was assessed through application of different questionnaires: VRS, 
SF-BPI, SF-MPQ and a brief questionnaire regarding pain. Most of the 
questionnaires share identical questions. To avoid redundancy in the 
interview, potential confusion and to save time, the investigator only 
asked patients about pain characteristics once, rather than, for example, 
three times in three different questionnaires. 
Distribution of pain – verbal rating scale (VRS) and  
body charts
Table 2 shows the ratings from the VRS from different body parts over 
time. Overall, the pain intensity – regardless of region – varied from 
patient to patient and was reported to range from mild to severe. Findings 
from distribution of pain showed that, for nearly half of all patients, pain 
seemed to occur in either the head-face-neck region, torso, legs or in all 
of the three areas. Pain was not present in the arms, shoulders or hands 
in this population as no patient reported pain in any of those regions. For 
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the head-face-neck region, two patients reported periodic occurrence of 
headaches, while one patient reported constant neck pain, which could 
become headache if untreated. Two of the patients, one with the periodic 
headaches and the other with neck pain, also reported that physical 
exertion could trigger pain in and around the orbital region, however, it 
had occurred over three months ago. For the chest-upper/lower back-
stomach region, two patients reported pain in the lower back (one 
constantly occurring, one periodic), while one patient experienced almost 
constant pain in both upper and lower back. Two of these patients also 
reported some pain in or around the stomach area (tightening pain). For 
the leg-feet region, three patients reported pain in the legs (two constant, 
one almost constant). One of the three also reported severe constant 
pain in the feet. The areas of frequently occurring pain in patients are 
depicted in Figure 2. Pain was reported to occur mostly in areas of the 
head, neck, upper back, lower back and legs. One patient, marking the 
area of the neck and shoulders, reported that the pain did not involve 
the shoulders but appeared on the entire upper back. Another patient 
reported pain on the plantar surface of the feet.
Short-form Brief Pain Inventory (SF-BPI)
The pain severity index from the SF-BPI is illustrated in Figure 3. The 
graph shows the mean score of pain for the past 24 hours when the pain 
was at the highest or lowest, the pain on average, and current pain. The 
mean pain severity indices show that patients experience mild (1–3) to 
moderate (4–6) pain over the past 24 hours. Table 3 shows mean pain-
related interferences. The pain-related interferences consist of seven 
domains (general activity, mood, walking ability, normal work, relations 
with other people, sleep and enjoyment of life), which patients were 
asked to rate on a scale from 0–10, where 0 = no interference and 
10 = complete interference, how much their pain affected these domains. 
The results show that pain – to some degree – affects patients in each 
of the seven domains. A Pearson correlation analysis was conducted to 
determine the relationship between the pain severity indices (average) 
and the pain-related interferences (see Table 3) Results show that a 
strong positive correlation was present for the pain severity index and 
‘ability to walk’ (r=0.889, n=5, p=0.044) and ‘general activity’ (r=0.901, n=6, 
p=0.014). Furthermore, a strong correlation was observed between the 
average pain severity index and pain-related interferences ‘mood’, ‘normal 
work’, ‘relations with other people’, and ‘sleep’, although these were 
not significant.
Short-form McGill Pain Questionaire (SF-MPQ)
Patients were asked to select pain descriptors that described their 
pain experiences the best. The most frequently chosen descriptors 
were: ‘throbbing’ (66.7%), ‘shooting’ (50%), ‘pricking’, ‘sharp’ (50%), 
‘cramping’ (50%), ‘pulling’ (50%), ‘burning’ (66.7%), ‘tender’ (66.7%), 
Table 1: Patient demographics 
Patient Age  
(years)
Gender Height 
(cm)
Weight  
(kg)
BMI  
(kg/m2)
Medications Other disorders
1 40 Female 164 70 26.03 Contraceptives, acetaminophen, ibuprofen
2 35 Female 173 66 22.05 Fish oil, vitamins, vitamin D, calcium, azathioprine, Benadryl® Pollen allergy
3 68 Female 177 70 22.34 Baclofen, sertralin, omeprazol, Betmiga (mirabegron), Trimopan® 
(trimethoprim)
Penicillin allergy
4 78 Male 173 78 26.06 Antidepressants Low metabolism
5 25 Female 180 71 21.91 Contraceptives (Femicept®), fish oil, vitamins (LongoVital®) Allergy, atopic dermatitis
6 36 Male 196 103 26.10 Magnesium, cannabis, Klyx®, vitamin D3, atorvastatin, baclofen
BMI = body mass index.
Table 2: Summary of verbal rating scale findings
Verbal rating scale (%)
Today (n) Past week (n) Past month (n) Past 3 months (n)
Head, face, neck No pain 4 (66.6%) 5 (83.3%) 3 (50.0%) 4 (66.6%)
Slight 1 (16.6%) 0 (0%) 0 (0%) 1 (16.6%) 
Moderate 1 (16.6%) 1 (16.6%) 1 (16.6%) 1 (16.6%)
Severe 0 (0%) 0 (0%) 2 (33.3%) 0 (0%)
Chest, upper and lower back, stomach No pain 5 (83.3%) 3 (50.0%) 3 (50.0%) 3 (50.0%)
Slight 0 (0%) 2 (33.3%) 2 (33.3%) 2 (33.3%)
Moderate 1 (16.6%) 1 (16.6%) 1 (16.6%) 1 (16.6%)
Severe 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Legs, feet No pain 4 (66.6%) 3 (50.0%) 3 (50.0%) 3 (50.0%)
Slight 1 (16.6%) 1 (16.6%) 1 (16.6%) 1 (16.6%)
Moderate 0 (0%) 1 (16.6%) 1 (16.6%) 1 (16.6%)
Severe 1 (16.6%) 1 (16.6%) 1 (16.6%) 1 (16.6%)
Patients were asked to rate their pain over the past 3 months in four different regions of the body: head, face and neck; shoulders, arms and hand (data not shown); chest, 
upper/lower back and stomach; and legs and feet. Results are presented as the number (percentage) (n [%]) of patients rating any of the four rating options: ‘no pain’, ‘slight 
pain’, ‘moderate pain’ and ‘severe pain’. Total number of patients = 6.
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‘exhausting’ (83.3%), and ‘annoying’ (83.3%). The results from the SF-
MPQ are illustrated in Figure 4, which shows the number of selected 
pain descriptors.
Brief questionnaire about pain
The brief questionnaire about pain was made for the sole purpose 
of investigating the quality of pain, and to identify if hypo- and/or 
hyperphenomena of pain exist and to what extent. Results showed that 
everyday stimuli such as light touch (e.g. clothing, bed linens, blankets, 
etc.), pressure (e.g. with a finger), and coldness and/or warmth (e.g. 
bathing) could trigger pain in 3–4 patients. Two of these patients reported 
that this occurred ‘always’, while the remaining patients reported that it 
occurred ‘almost never’ and ‘slightly’. None of these patients reported 
that such phenomena occurred for the head, face or neck. However, 
it was reported that such phenomena commonly occurred for the 
areas of the lower back and legs. Only one patient experienced pain 
attacks and a numb sensation in lower back and legs and that this 
occurred ‘always’. 
Illness perception
Results from the BIPQ showed a mean total score of 38.7 arbitrary units 
(a.u.) ± 9.5 (Table 4). This indicates that the patients – to some degree – 
think negatively about their disease. In particular, item 2 (timeline: ‘how 
long do you think you will be sick?’) rated highest (9.0 a.u. ± 0.6), indicating 
that patients believed that the prospect of recovery is poor. The causal 
item, i.e. item 9, consisted of the patients’ own thoughts about what may 
have caused their diagnosis. Most patients did not know why and could 
not give their own ideas to causes of their illness. However, those who did 
answer were somewhat unanimous in their answers: their disease was 
stress-induced or caused by lifestyle factors, e.g., smoking. One patient 
reported that genetic predisposition (autoimmunity runs in the family) may 
play a role. Another patient reported that prior infections may have caused 
the disease. 
Fatigue
Similar to the questionnaires of pain, many questions were identical 
for the fatigue questionnaires. As a specific scoring system was used 
to analyse these questionnaires, identical questions were repeated. To 
avoid confusion, the investigator explained to patients that they might 
have to answer identical questions in different questionnaires. They 
were also instructed to not think too much about their answer, however, 
they should answer what they felt about their situation. Scores from one 
patient were not obtained due to discontinuation of the interview.
Fatigue Scale for Motor and Cognitive Functions (FSMC) and 
Modified Fatigue Impact Scale (MFIS)
The mean total score of the FSMC was calculated, which showed a 
mean score of 50.8 (a.u.) ± 7.3. This indicates that the patients suffer 
from fatigue as a result of their disease. The score was divided into two 
subscales: a mental and a fatigue subscale. The mental subscale had a 
mean score of 25.5 (a.u.) ± 4.5, while the fatigue subscale had a mean 
score of 25.3 (a.u.) ± 3.6, indicating that mental fatigue and physical 
fatigue equally contributed to an overall fatigue score in the patients. 
The MFIS is a questionnaire assessing fatigue over a period of 4 weeks. 
A mean total MFIS score was calculated, which showed a mean score of 
23.0 (a.u.) ± 6.1, indicating that fatigue had had an impact on the patient’s 
everyday life for the past 4 weeks.
Depression and anxiety
The questionnaires of depression and anxiety overlapped to some 
extent, similar to the questionnaires of pain and fatigue. Patients were 
asked to answer the questions regardless of their repetition. This was 
done as each answer represents a certain score, which would be used 
in a specific scoring system. Scores from one patient were not obtained 
due to discontinuation of the interview.
Beck Depression Inventory Fast Screen (BDI-FS) and Hospital 
Scale for Anxiety and Depression (HADS)
The results from the BDI-FS showed a total mean score of 1.6 ± 0.8, 
which indicates that the patients suffer from minimal depression. 
Figure 2: Superimposed illustration of frequently occurring 
painful areas
Patients were asked to specifically describe where the pain occurred. The investigator 
marked out areas according to patient descriptions. One patient reported pain under 
the foot; this could not be sketched on the illustration. Patients reported frequently 
occurring pain in areas of head, neck, upper back, lower back, and legs. Total number 
of patients = 6. L = left; R = right.
Figure 3: Mean pain severity indices
The investigator asked the patients to rate their pain with a scale ranging from 0–10  
(0 = no pain, 10 = worst imaginable pain) over a time period of 24 hours. Patients were 
asked to rate the severity of their pain when it was worst and mildest, what it was on 
average, and their current pain status. Mean pain scores were subcategorised into no 
pain (0), mild pain (1–3), moderate pain (4–6) and severe pain (7–10). Error bars ± SE. 
Total number of patients = 6. SE = standard error of the mean.
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The HADS questionnaire is divided into an anxiety subscale and a 
depression subscale. Results from the HADS showed a mean score of 
4.4 (a.u.) ± 2.1 for the anxiety dimension indicating no presence of anxiety, 
while a mean score of 1.6 (a.u.) ± 0.8 for the depression dimension 
indicates no depression. However, one patient scored as high as 12 on 
the anxiety subscale, indicating a high degree of anxiety.
Discussion
The present study investigated the prevalence and pattern of pain 
and abnormalities of somatosensory function in NMOSD patients, with 
additional attention to craniofacial pain and headaches. The impact of 
fatigue, anxiety and depression on pain experiences in these patients was 
also studied. Through a series of questionnaires, this study demonstrated 
Table 3: Scores for mean pain-related interferences and Pearson’s correlation analysis
Pain-related interference
General  
activity
Mood Walking  
ability
Normal  
work
Relations with 
other people
Sleep Enjoyment  
of life
Mean ± SE 2.0 ± 1.1 1.2 ± 0.8 0.8 ± 0.7 2.5 ± 1.7 0.8 ± 0.8 1.8 ± 1.3 1.3 ± 1.1
Pearson’s correlation coefficient (r) 0.901* 0.603 0.889* 0.664 0.774 0.586 0.412
Significance (p≤0.05) 0.014* 0.205 0.044* 0.150 0.071 0.221 0.417
Patients (n) 6 6 5 6 6 6 6
Mean pain-related interferences were rated on a scale ranging from 0–10 (0 = not at all, 10 = completely). Correlation between the pain severity index (average) and the pain-
related interferences revealed a strong correlation for pain severity index and ‘general activity’, ‘walking ability’, ‘mood’, ‘normal work’, ‘relations with other people’, and ‘sleep’. A 
Pearson correlation coefficient of 0.5–1.0 indicates a strong correlation, while a coefficient of 0.3–0.5 indicates moderate correlation and, lastly, 0.1–0.3 indicates low correlation. 
Only 5 patients rated in the item ‘walking ability’, as one patient was paralysed from chest to feet. Significant values are indicated with an asterisk (*). Total number of patients = 
5–6. SE = standard error of the mean.
Table 4: Mean Brief Illness Perception Questionnaire scores (± SE) for each item of the questionnaire and a total  
mean score
Mean BIPQ scores (a.u.) ± SE
Consequence Timeline Personal 
control
Treatment 
control
Identity Coherence Emotional 
representation
Concern 
understanding
Total score
5.5 ± 1.4 9.0 ± 0.6 3.8 ± 2.0 3.8 ± 2.0 4.5 ± 1.1 4.7 ± 1.4 3.8 ± 1.7 4.7 ± 1.5 38.7 ± 9.5
Patients were asked to answer each item with the use of a scale ranging from 0–10. The higher the rating, the stronger the endorsement of that item. Each item represents 
different dimensions (consequences, timeline, personal control, treatment control, identity, coherence, emotional representation, concern understanding and, lastly, the causal 
item). The last item (causal item) is not shown in the table. Total number of patients = 6. a.u. = arbitrary units; BIPQ = Brief Illness Perception Questionnaire; SE: standard error of 
the mean. 
Figure 4: Bar chart of number of chosen pain descriptors from the Short-form McGill Pain Questionnaire 
Patients were asked to choose the best descriptors to reflect on their pain experiences. Total number of patients = 6.
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that pain was present in these patients and that in half of them pain 
seems to dominate in either the head-face-neck region, back, legs, or 
in all three areas. For the back-region and legs, patients experienced 
mild to severe pain. Two patients experienced frequently occurring 
headaches and one had headaches following neck pain. This occurred 
frequently over a three-month period and was described as ranging from 
mild to severe. No alteration was reported in terms of somatosensory 
function within the craniofacial region, but hypo- or hyperphenomena 
were present in legs. While anxiety and depression appear not to affect 
this group of patients, the results show that fatigue plays a great role in 
their everyday life. The inter-relationship between fatigue, pain, anxiety 
and depression has been found for many pain conditions4,17,18 and these 
findings call for further investigation of the fatigue–pain relationship in 
these patients.
Overall pain experience
Pain is a prevalent symptom in NMOSD and it has been reported that 
a majority of patients suffering from this disease complain about 
constant pain.18 This was also the case for the patients interviewed in 
this study. When reviewing the results from the VRS and SF-BPI, pain 
was found to be at least more or less constant within the last three 
months, and even on the day of the interview patients experienced 
mild to moderate pain. In general, pain seemed to occur in the head-
face-neck region, torso and legs; however, it was present in the legs 
and in the lower back predominantly. This is in agreement with existing 
studies reporting that pain is most prevalent in legs (89%) and back 
(93%).1,11–13 These studies also state that ‘burning’, ‘exhausting’ and 
‘sharp’ are used frequently to describe pain characteristics in these 
patients. Similarly, the results from the SF-MPQ used in the present 
study showed that ‘burning’ (66.7%), ‘exhausting’ (83.3%) and ‘sharp’ 
(50%) were also the most frequently chosen descriptors. In addition to 
that, often-chosen descriptors were also ‘throbbing’ (66.7%), ‘shooting’ 
(50%), ‘pricking’ (50%), ‘cramping’ (50%), ‘pulling’ (50%),   ‘tender’ 
(66.7%) and, lastly, ‘annoying’ (83.3%). Selection of these descriptors 
by the patients indicates that the pain experienced is mostly pain 
with characteristics of pain with neuropathic origin.19 These patients 
seemed to suffer from allodynia. This became evident when reviewing 
results from the brief questionnaire about pain where it was found 
that everyday stimuli such as light touch (e.g. with clothing), pressure 
(e.g. with a finger), and coldness and/or warmth (e.g. from bathing) 
could elicit pain or worsen pain. Similar observations were reported 
by Pellkofer et al., where patients had significant heat hyperalgesia 
and showed a strong tendency towards pain sensitivity for pin-prick 
and light touch with brush stroking.12 However, it should be noted 
that, for the present study, merely half of the patients experienced 
this hyper-responsiveness to non-painful or painful stimuli, but not 
in the craniofacial region. Thermal hyperalgesia is usually attributed 
to peripheral sensitisation of afferent C-fibres, which typically is a 
sign of inflammatory processes.17 However, Pellkofer et al. found that 
the presence of hyper-responsiveness to thermal stimuli, especially 
in response to noxious heat, highly depended on  the presence of 
spinal lesions and that hyperalgesia was particularly severe after 
a NMOSD relapse, which causes inflammatory demyelination of the 
spinal cord.12,20,21 It has been proposed that the degree of thermal 
hyperalgesia corresponds to the current level of NMOSD-associated 
neuro-inflammation.12 This could explain the observations from this 
study and why some patients experience hyperalgesia, and others do 
not. Moreover, this study cannot rule out interference with analgesic 
treatment and therefore it remains unknown if pain and hypo-/
hyperphenomena could have been more prevalent or more severe 
without having analgesics on board. 
To further investigate the impact of pain in the patients, pain-related 
interferences were assessed with the SF-BPI. This section of the 
questionnaire consists of seven items of everyday tasks and situations. 
Pain was found to correlate with pain-related interferences, at least 
significantly in the items ‘general activity’ and ‘ability to walk’. Strong 
correlations were also found between pain and ‘mood’, ‘normal work’, 
‘relations with other people’, and ‘sleep’, which indicates that pain indeed 
affects patients’ everyday life, at least 24 hours prior to the interview. This 
finding is in accordance with previous studies also showing a correlation 
between pain and pain-related interferences,1,11,13 including sleep15 and 
fatigue.16 It should be noted that for each of the items, almost all scores 
were below 2 on a scale ranging from 0–10. In particular, the items ‘ability 
to walk’ and ‘relations with other people’ were scored quite low (0.8), 
therefore, it can be questioned whether or not, at least for these two 
correlations, this is noteworthy information. Also, for the item ‘ability to 
walk’, scores were only obtained from five patients, as one patient did 
not want to rate because she was paralysed from her chest to her feet. 
Nonetheless, as half of the patients reported pain at the time of interview 
or within the 3 months preceding the interview, the data from this study 
emphasise the relatively high incidence of pain in NMOSD patients, 
which in turn accentuates the need for further investigation.
Pattern of headaches and craniofacial pain
While little is known about general pattern of pain in NMOSD patients, 
prevalence and pattern of headache and facial pain are highly 
underreported in this group of patients.22 Some studies have, however, 
attempted to examine headaches and facial pain; nevertheless, results 
are limited and indistinct and the type of headache and implicated 
pathophysiology of pain largely vary. The prevalence of headaches 
or craniofacial pain observed in this study was not astoundingly high; 
however, it was noteworthy.  Since patient journals (including imaging of 
CNS) were not assessed in this study, the observations from this interview 
cannot be linked to clinical findings in the patients. The localisation of 
lesions in the CNS seems to have a great impact.22,23 The prevalence of 
headaches is higher in patients with medulla oblongata lesions than those 
without lesions in this area.23 In another study exploring the prevalence 
of brainstem symptoms in NMOSD patients, it was suggested that pain 
in the facial region and headache might occur as a result of trigeminal 
neuralgia. Consequently, as no assessment of CNS imaging was made, 
no strong conclusion regarding the cause of headache or craniofacial 
pain can be made, at least not at present; but more investigations would 
facilitate a better understanding of potential underlying mechanisms. 
Two of the three patients also reported periodic pain in the orbital region, 
often occurring after physical exertion. This observation is close to that 
of Qian et al., who reported a rather high prevalence of retro-orbital pain 
(55.2%).11 Pain in the orbital regions is often caused by ON.4,22 The present 
study cannot conclude whether or not ON attacks may explain the orbital 
pain pattern observed. Furthermore, the patients did not report that they 
suffered from ON. This could have been clarified if patients’ full medical 
journals had been accessible. All three patients experiencing headaches, 
orbital pain and neck pain were women. Kim et al. found a significant 
gender difference in regards to site of attack and severity of symptoms 
and women presented more frequently with relapses.24 In general, there 
is a female preponderance in NMOSD cases.6 Since both the sample size 
and proportion of male patients in this study are small, it is not possible 
to conclude whether gender effects cause these observations. 
Considering some limitations, overall, this study revealed that 
headaches do occur frequently and are mild to severe in intensity. 
Additionally, despite a relatively small sample size and a skewed 
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gender distribution, this study demonstrated that pain occurs in areas 
that are frequently overlooked by other pain-related investigations 
in NMOSD. Furthermore, these findings highlight that headaches and 
craniofacial pain do occur frequently in this group of patients, much 
more prevalently than first appreciated. This also highlights the value 
and necessity of further investigations. 
Illness perception
The BIPQ is a model that allows quick assessment of the illness 
perception of patients suffering from diseases or illnesses, and the higher 
the score, the worse the perception of one’s illness.18 The present study 
demonstrated that, with a mean score of 38 out of 90, patients think 
negatively about their disease, at least to some noteworthy degree. One 
item of the questionnaire scored exceptionally high for all patients, the 
‘timeline’ item. With a score of 9 out of 10 on the scale, it indicates that 
patients feel they remain sick for a long time. These findings are partially 
in accordance with existing literature. Similar results have been found by 
Zhao et al. and Qian et al.,11,13 who explored NMOSD patients’ evaluation 
of their own health status through the Short-form Health Survey and 
found negative evaluations of own health status in these patients. To the 
best of the authors’ knowledge, the present study is the first to report 
illness perception using the BIPQ in NMOSD patients.
Research has demonstrated the importance of illness representations 
to patient behavior.25 Changing illness perception has been found 
to improve disease recovery in various illnesses and diseases, and 
consequently this has helped patients cope better with their disease.26 
Therefore, the findings of this study may assist in better understanding 
of patients’ own perception on their diagnosis, their feelings, and their 
concerns. This in turn may facilitate the way that clinicians can help 
patients to cope with their illness. 
Fatigue, anxiety and depression
NMOSD is associated with reduced quality of life due to the fact that 
some factors such as fatigue, anxiety, and depression have been known 
to impact the patients negatively and to a large extent.10,27 Fatigue 
significantly lowers quality of life27–29 and it is present in many neurological 
disorders including NMOSD.16 Similarly, patients in the present study 
were found to suffer from fatigue. This observation is interesting as 
fatigue is a common comorbidity of NMOSD and it has been proposed 
that this factor may also enhance the perception of pain.9 Additionally, 
the interrelationship between fatigue and pain can be a vicious cycle 
for some patients. This becomes evident when reviewing individual 
results. Intriguingly, the same patients who scored highly on fatigue 
questionnaires were also the patients who reported frequent pain. 
Observations from this study accentuate the importance of considering 
comorbidities, such as fatigue and sleep disturbances15 in NMOSD 
patients. Further research is needed to highlight this situation, and find 
ways to overcome fatigue as a strategy to reduce pain and suffering in 
these patients. 
Anxiety and depression are highly prevalent in NMOSD.4,10 Contradictorily, 
this study found that anxiety and depression did not affect patients, at 
least not to a high degree, which is similar to what has been concluded in 
other studies.1,4,11,13 The BDI-FS did, however, reveal a tendency of minimal 
depression in the patients. This result is still not close to the outcomes 
of other studies on this point.1,4,11,13 It should be highlighted that the 
small sample size might have influenced the outcome here, as for both 
BDI-FS and HADS, scores were computed for only five patients. Further 
investigations are warranted to demonstrate whether a relationship 
exists between anxiety and depression and pain, and to what extent. This 
is of a great value, because the co-existence of pain with depression and 
anxiety is well known30–32 and targeting either condition would improve 
the overall quality of life of affected patients. 
Limitations, challenges and future perspectives
This study is not exempt from limitations. The study size was rather small. 
This stems from the fact that NMOSD is a rare autoimmune disease and 
recruiting sufficient numbers of patients, who can meet the inclusion 
criteria, is a difficult and time-consuming task. A recent study33 has 
looked into the incidence of NMOSD in the central Denmark region and 
has reported a considerably low incidence rate. The estimated incidence 
of NMO (2006 criteria) and NMOSD (2015 criteria) were reported to be 
0.08 and 0.12 per 100,000 person-years, respectively.33
In addition, a lot of demographic information was missing. This was 
due to the fact that the correspondence and application process for 
obtaining permissions from the Data Protection Agency to access the 
patient’s full medical journal requires sufficient time and resources. 
Hence, only a limited amount of information could be obtained and used 
in this pilot study. 
The study was conducted by a telephone interview as a consequence 
of the distances between the investigator and the patients. It would, 
however, have been more advantageous to interview patients face-to-
face. This style would potentially avoid misunderstandings that might 
occur during a telephone interview and would have given patients more 
trust in the interviewer.  However, one should consider that face-to-face 
meeting is more time-consuming and would require flexibility from both 
the investigator and the patient to meet at a suitable time and location. 
The interview was designed as a qualitative structured interview. This 
means that patients were asked a specific question, to which they could 
answer with pre-defined answers only; they could not answer a question 
freely. This was highlighted by patients themselves as an issue, stating 
that sometimes it was felt that the pre-defined answers did not address 
the question well enough, and having the opportunity to answer freely 
would have given a better answer. It should be noted that patients were 
indeed given the opportunity to address important issues if they wanted 
to share them. The structured interview design was chosen for this study 
because several questionnaires were considered to be used in order 
to thoroughly investigate pain and related issues. To accommodate the 
needs of patients for sharing important issues, it is proposed that both a 
structured (questionnaires) and an unstructured (free talk) design should 
be considered. 
The interview was designed in such a way to last a maximum of one 
hour; however, this could not be adhered to in the actual interview. 
The investigator ran some small pilot interviews on healthy subjects to 
ensure that the interview did not exceed one hour. No pilot interview 
exceeded one hour. It is the investigator’s opinion that the actual patient 
interviews exceeded this one-hour time frame because the patients 
wanted to share more information than just answering the structured 
questions. This also highlights the aforementioned challenge. Almost 
all patients were very interested in sharing their experiences, simply 
because they desired to help. This should be taken into account in 
further investigations. 
The questionnaires utilised in this study were several, and were time 
consuming to fill out.  Additionally, many of the questionnaires were quite 
similar to each other. This was especially true for the FSMC and MFIS, 
the BDI-FS and HADS. Some of the questionnaires regarding pain were 
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also quite alike; however, the investigator ensured that questions did not 
repeat throughout the interview. For the fatigue, anxiety and depression 
questionnaires, this approach was not possible due to different scoring 
systems applied on the questionnaires. In future, it may not be necessary 
to repeat all questionnaires, but merely one questionnaire for fatigue, and 
one for anxiety and depression. Another approach could be to design a 
distinct questionnaire, including all aspects of pain, illness perception, 
fatigue, anxiety and depression. In doing so, redundancy must be avoided 
to lead to an easy and speedy process of interviews. However, it should 
be considered that such a custom-made questionnaire developed from 
the merging of several existing questionnaires would firstly need a 
validation process. Questionnaires that are valid are preferable due to 
their high repeatability.31
Since headache and craniofacial pain in this group of patients are 
still under-recognised, and subsequently have not been studied 
systematically, we believe the findings from this trial would still 
attract attention and stimulate further research. Choi et al. highly 
emphasise this in a case report of a young man suffering from 
intractable headaches.34 This young man suffered from headache 
with radiation to the posterior neck for several weeks. He was initially 
mistakenly diagnosed with cervicogenic headache and was treated 
with a nerve block in the occipital, which proved unsuccessful in 
relieving the headache.34 Further investigation of the patient and his 
clinical presentations finally led to a NMOSD diagnosis.34 Therefore, 
it is essential to take investigations further in order for scientists 
and clinicians to know more about the pattern of headaches or 
craniofacial pain in NMOSD. This knowledge may also prove useful 
in identifying distinct clinical presentations, or a proper and faster 
treatment choice. 
Conclusion
This study demonstrated that headaches and some orbital pain occur 
in an episodic to frequent fashion, and that pain in other parts of the 
patient’s body seems to occur in a frequent to constant manner. More 
investigation is warranted to explore this finding as this in turn may 
contribute to better understanding of the underlying mechanisms of not 
only pain generation in general, but also headaches and craniofacial pain 
in this group of patients. This will eventually open up an avenue for better 
management of pain in NMOSD patients. 
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